JP2010515663A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2010515663A5 JP2010515663A5 JP2009527641A JP2009527641A JP2010515663A5 JP 2010515663 A5 JP2010515663 A5 JP 2010515663A5 JP 2009527641 A JP2009527641 A JP 2009527641A JP 2009527641 A JP2009527641 A JP 2009527641A JP 2010515663 A5 JP2010515663 A5 JP 2010515663A5
- Authority
- JP
- Japan
- Prior art keywords
- salt
- fluoro
- hydrate
- oxoquinoline
- dihydro
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000003839 salts Chemical class 0.000 claims description 15
- 150000001875 compounds Chemical class 0.000 claims description 7
- 239000002253 acid Substances 0.000 claims description 4
- 239000004480 active ingredient Substances 0.000 claims 2
- QQQJLSWMKXOGDF-BHINWFLXSA-N 7-[(3as,6ar)-6a-amino-3a-fluoro-3,4,5,6-tetrahydro-1h-cyclopenta[c]pyrrol-2-yl]-6-fluoro-1-[(1r,2s)-2-fluorocyclopropyl]-8-methoxy-4-oxoquinoline-3-carboxylic acid Chemical compound COC1=C(N2C[C@@]3(F)CCC[C@@]3(N)C2)C(F)=CC(C(C(C(O)=O)=C2)=O)=C1N2[C@@H]1C[C@@H]1F QQQJLSWMKXOGDF-BHINWFLXSA-N 0.000 claims 1
- QEESVFWVTXIORT-GWXMJYEKSA-N 7-[(3as,7as)-3a-amino-1,3,4,6,7,7a-hexahydropyrano[3,4-c]pyrrol-2-yl]-6-fluoro-1-[(1r,2s)-2-fluorocyclopropyl]-8-methoxy-4-oxoquinoline-3-carboxylic acid Chemical compound COC1=C(N2C[C@]3(N)COCC[C@H]3C2)C(F)=CC(C(C(C(O)=O)=C2)=O)=C1N2[C@@H]1C[C@@H]1F QEESVFWVTXIORT-GWXMJYEKSA-N 0.000 claims 1
- CNAIVPGMJYSOAK-QHIFUMFDSA-N 7-[(3as,7as)-3a-amino-1,3,4,6,7,7a-hexahydropyrano[3,4-c]pyrrol-2-yl]-6-fluoro-1-[(1r,2s)-2-fluorocyclopropyl]-8-methyl-4-oxoquinoline-3-carboxylic acid Chemical compound CC1=C(N2C[C@]3(N)COCC[C@H]3C2)C(F)=CC(C(C(C(O)=O)=C2)=O)=C1N2[C@@H]1C[C@@H]1F CNAIVPGMJYSOAK-QHIFUMFDSA-N 0.000 claims 1
- LWEREWZZYXQEDT-FLBYAOOYSA-N 7-[(3as,7as)-7a-amino-1,3,3a,4,6,7-hexahydropyrano[3,4-c]pyrrol-2-yl]-6-fluoro-1-[(1r,2s)-2-fluorocyclopropyl]-8-methoxy-4-oxoquinoline-3-carboxylic acid Chemical compound COC1=C(N2C[C@]3(N)CCOC[C@H]3C2)C(F)=CC(C(C(C(O)=O)=C2)=O)=C1N2[C@@H]1C[C@@H]1F LWEREWZZYXQEDT-FLBYAOOYSA-N 0.000 claims 1
- WNUTUOYLSLQFOM-YWCVGHFTSA-N 7-[6-amino-8-azatricyclo[4.3.0.01,3]nonan-8-yl]-6-fluoro-1-[(1r,2s)-2-fluorocyclopropan-1-yl]-8-methoxy-4-oxo-1,4-dihydroquinoline-3-carboxylic acid Chemical compound COC1=C(N2CC3(N)CCC4CC43C2)C(F)=CC(C(C(C(O)=O)=C2)=O)=C1N2[C@@H]1C[C@@H]1F WNUTUOYLSLQFOM-YWCVGHFTSA-N 0.000 claims 1
- BNNFXUCYZQQRCR-UUHZNHMGSA-N CC1=C(N2CC3(N)CCC4CC43C2)C(F)=CC(C(C(C(O)=O)=C2)=O)=C1N2[C@@H]1C[C@@H]1F Chemical compound CC1=C(N2CC3(N)CCC4CC43C2)C(F)=CC(C(C(C(O)=O)=C2)=O)=C1N2[C@@H]1C[C@@H]1F BNNFXUCYZQQRCR-UUHZNHMGSA-N 0.000 claims 1
- 239000003242 anti bacterial agent Substances 0.000 claims 1
- 150000004677 hydrates Chemical class 0.000 claims 1
- 241001465754 Metazoa Species 0.000 description 4
- -1 inorganic acid salts Chemical class 0.000 description 4
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 3
- 150000003863 ammonium salts Chemical class 0.000 description 2
- 150000003871 sulfonates Chemical class 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
- MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical class CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 description 1
- 229910002651 NO3 Inorganic materials 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical class CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 239000003905 agrochemical Substances 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 159000000007 calcium salts Chemical class 0.000 description 1
- 150000007942 carboxylates Chemical class 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- 229910003002 lithium salt Inorganic materials 0.000 description 1
- 159000000002 lithium salts Chemical class 0.000 description 1
- 159000000003 magnesium salts Chemical class 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2009527641A JP5197606B2 (ja) | 2007-01-05 | 2007-12-28 | フューズ置換型アミノピロリジン誘導体 |
Applications Claiming Priority (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2007000667 | 2007-01-05 | ||
| JP2007000667 | 2007-01-05 | ||
| JP2007074991 | 2007-03-22 | ||
| JP2007074991 | 2007-03-22 | ||
| PCT/JP2007/075434 WO2008082009A2 (en) | 2007-01-05 | 2007-12-28 | Fused substituted aminopyrrolidine derivative |
| JP2009527641A JP5197606B2 (ja) | 2007-01-05 | 2007-12-28 | フューズ置換型アミノピロリジン誘導体 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2010515663A JP2010515663A (ja) | 2010-05-13 |
| JP2010515663A5 true JP2010515663A5 (enExample) | 2011-02-17 |
| JP5197606B2 JP5197606B2 (ja) | 2013-05-15 |
Family
ID=39522355
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009527641A Expired - Fee Related JP5197606B2 (ja) | 2007-01-05 | 2007-12-28 | フューズ置換型アミノピロリジン誘導体 |
Country Status (24)
| Country | Link |
|---|---|
| US (2) | US8618094B2 (enExample) |
| EP (2) | EP2540715A1 (enExample) |
| JP (1) | JP5197606B2 (enExample) |
| KR (1) | KR101419085B1 (enExample) |
| AR (1) | AR064753A1 (enExample) |
| AU (1) | AU2007339692B2 (enExample) |
| BR (1) | BRPI0720771A2 (enExample) |
| CA (1) | CA2674369C (enExample) |
| CL (1) | CL2008000026A1 (enExample) |
| CY (1) | CY1114444T1 (enExample) |
| DK (1) | DK2097400T3 (enExample) |
| ES (1) | ES2428344T3 (enExample) |
| IL (1) | IL199694A (enExample) |
| MX (1) | MX2009007291A (enExample) |
| MY (1) | MY162052A (enExample) |
| NO (1) | NO20092804L (enExample) |
| NZ (1) | NZ577214A (enExample) |
| PE (1) | PE20081631A1 (enExample) |
| PL (1) | PL2097400T3 (enExample) |
| PT (1) | PT2097400E (enExample) |
| RU (1) | RU2443698C2 (enExample) |
| SI (1) | SI2097400T1 (enExample) |
| TW (1) | TWI409068B (enExample) |
| WO (1) | WO2008082009A2 (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2012018105A1 (ja) * | 2010-08-06 | 2012-02-09 | 第一三共株式会社 | 抗菌化合物の結晶 |
| WO2014152317A2 (en) * | 2013-03-15 | 2014-09-25 | Melinta Therapeutics, Inc. | Methods of treating gonorrhea infections using quinolone antibiotics |
| CN109069498B (zh) | 2016-02-12 | 2021-08-17 | 细胞动力学股份有限公司 | 四氢异喹啉衍生物 |
| CA3158628A1 (en) * | 2019-10-23 | 2021-04-29 | Taigen Biotechnology Co., Ltd. | Quinolone carboxylic acid derivatives |
| CA3227204A1 (en) * | 2021-07-22 | 2023-01-26 | The Texas A&M University System | Activated ferrate solutions and methods thereof |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS61282382A (ja) | 1985-06-06 | 1986-12-12 | Dainippon Pharmaceut Co Ltd | フエニル置換１，８−ナフチリジン誘導体、そのエステルおよびその塩 |
| EP0242789A3 (en) | 1986-04-25 | 1990-09-05 | Dainippon Pharmaceutical Co., Ltd. | Novel quinoline derivates and processes for preparation thereof |
| JPH0676400B2 (ja) * | 1987-08-25 | 1994-09-28 | 大日本製薬株式会社 | 新規ピリドンカルボン酸誘導体、そのエステルおよびその塩 |
| MY105136A (en) | 1988-04-27 | 1994-08-30 | Daiichi Seiyaku Co | Optically active pyridonecarboxylic acid derivatives. |
| JP2844079B2 (ja) * | 1988-05-23 | 1999-01-06 | 塩野義製薬株式会社 | ピリドンカルボン酸系抗菌剤 |
| JP2807277B2 (ja) | 1988-08-31 | 1998-10-08 | 第一製薬株式会社 | スピロ化合物 |
| JPH0278659A (ja) * | 1988-09-12 | 1990-03-19 | Shionogi & Co Ltd | アザビシクロアルカン類化合物 |
| EP0677522A4 (en) | 1992-12-28 | 1995-12-27 | Yoshitomi Pharmaceutical | 8-methoxyquinolonecarboxylic acid derivative. |
| JPH06345261A (ja) | 1993-04-16 | 1994-12-20 | Daihen Corp | 自動搬送装置の搬送用ハンド |
| DE69526595T2 (de) | 1994-02-04 | 2002-08-22 | Dainippon Pharmaceutical Co., Ltd. | Pyridoncarbonsäurederivate substituiert von bicyclischer aminogruppe, deren ester und salze, und bicyclisches amin als zwischenprodukt davon |
| DE4435479A1 (de) | 1994-10-04 | 1996-04-11 | Bayer Ag | Chinolon- und Naphthyridoncarbonsäure-Derivate |
| WO1996023782A1 (en) * | 1995-02-02 | 1996-08-08 | Daiichi Pharmaceutical Co., Ltd. | Heterocyclic compounds |
| JPH11510478A (ja) * | 1995-06-06 | 1999-09-14 | アボツト・ラボラトリーズ | キノリジノン型化合物 |
| JP4132155B2 (ja) * | 1996-10-25 | 2008-08-13 | 第一三共株式会社 | 三環性アミン誘導体 |
| BR9915599A (pt) * | 1998-11-24 | 2001-11-20 | Daiichi Seiyaku Co | Derivados de aminometilpirrolidina substituìdacom cicloalquila |
| AU2002224088B2 (en) * | 2000-11-24 | 2007-06-14 | Meiji Seika Kaisha, Ltd. | Novel carbapenem derivatives |
| WO2005049602A1 (en) * | 2003-11-18 | 2005-06-02 | Warner-Lambert Company Llc | Quinolone antibacterial agents |
| US7563805B2 (en) * | 2005-05-19 | 2009-07-21 | Daiichi Pharmaceutical Co., Ltd. | Tri-, tetra-substituted-3-aminopyrrolidine derivative |
-
2007
- 2007-12-28 WO PCT/JP2007/075434 patent/WO2008082009A2/en not_active Ceased
- 2007-12-28 ES ES07860629T patent/ES2428344T3/es active Active
- 2007-12-28 MY MYPI20092809A patent/MY162052A/en unknown
- 2007-12-28 NZ NZ577214A patent/NZ577214A/en not_active IP Right Cessation
- 2007-12-28 PL PL07860629T patent/PL2097400T3/pl unknown
- 2007-12-28 JP JP2009527641A patent/JP5197606B2/ja not_active Expired - Fee Related
- 2007-12-28 AU AU2007339692A patent/AU2007339692B2/en not_active Ceased
- 2007-12-28 EP EP12186361A patent/EP2540715A1/en not_active Withdrawn
- 2007-12-28 MX MX2009007291A patent/MX2009007291A/es active IP Right Grant
- 2007-12-28 KR KR1020097013835A patent/KR101419085B1/ko not_active Expired - Fee Related
- 2007-12-28 PT PT78606290T patent/PT2097400E/pt unknown
- 2007-12-28 EP EP07860629.0A patent/EP2097400B1/en not_active Not-in-force
- 2007-12-28 RU RU2009129975/04A patent/RU2443698C2/ru not_active IP Right Cessation
- 2007-12-28 BR BRPI0720771-9A2A patent/BRPI0720771A2/pt not_active IP Right Cessation
- 2007-12-28 SI SI200731318T patent/SI2097400T1/sl unknown
- 2007-12-28 DK DK07860629.0T patent/DK2097400T3/da active
- 2007-12-28 CA CA2674369A patent/CA2674369C/en not_active Expired - Fee Related
-
2008
- 2008-01-03 TW TW097100126A patent/TWI409068B/zh not_active IP Right Cessation
- 2008-01-04 AR ARP080100035A patent/AR064753A1/es not_active Application Discontinuation
- 2008-01-04 CL CL200800026A patent/CL2008000026A1/es unknown
- 2008-01-04 PE PE2008000090A patent/PE20081631A1/es not_active Application Discontinuation
-
2009
- 2009-07-02 US US12/459,612 patent/US8618094B2/en not_active Expired - Fee Related
- 2009-07-05 IL IL199694A patent/IL199694A/en not_active IP Right Cessation
- 2009-08-04 NO NO20092804A patent/NO20092804L/no not_active Application Discontinuation
-
2013
- 2013-09-30 CY CY20131100845T patent/CY1114444T1/el unknown
- 2013-11-19 US US14/084,485 patent/US20140142096A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20210343T1 (hr) | Soli ili ko-kristali 3-(3-dimetilamino-1-etil-2-metil-propil)-fenola | |
| JP2013526580A5 (enExample) | ||
| JP2016106150A5 (enExample) | ||
| HRP20140780T4 (hr) | Amorfni i kristalinični oblik genz 112638 hemitartrata kao inhibitor glukozilceramid sintaze | |
| JP2011201907A5 (enExample) | ||
| JP2015527402A5 (enExample) | ||
| JP2010515663A5 (enExample) | ||
| JP2014218522A5 (enExample) | ||
| BR112012019374A2 (pt) | composição farmacêutica, pellet de liberação prolongada, composição farmacêutica oral, método para tratamento de uma doença neurodegenerativa ou um dano ao sistema nervoso em um indivíduo necessitado do mesmo e método para preparação de uma formulação de liberação prolongada de um agente ativo | |
| WO2011118976A3 (en) | Pharmaceutical composition for the prevention or the treatment of non-alcoholic fatty liver disease and the method for prevention or treatment of non-alcoholic fatty liver disease using the same | |
| HRP20171742T4 (hr) | 2,4,6-trifluor-n-[6-(1-metilpiperidin-4-karbonil)piridin-2-il]benzamid, namijenjen liječenju migrene oralnom ili intravenskom primjenom | |
| JP6116674B2 (ja) | （１ｒ，４ｒ）−６’−フルオロ−Ｎ，Ｎ−ジメチル−４−フェニル−４’，９’−ジヒドロ−３’Ｈ−スピロ［シクロヘキサン−１，１’−ピラノ−［３，４，ｂ］インドール］−４−アミンおよびプロピオン酸誘導体を含む医薬組成物 | |
| US6995190B2 (en) | Method and treatment with ketoprofen solution | |
| CA2964684A1 (en) | Composition for the treatment of conditions involving muscular pain | |
| RU2016137926A (ru) | Композиции грапипранта и способы их применения | |
| HK1203394A1 (en) | Ghrelin receptor agonists for the treatment of achlorhydria | |
| JP2019510834A5 (enExample) | ||
| HRP20211661T1 (hr) | Igmezin, namijenjen upotrebi u liječenju alzheimerove bolesti | |
| JP2019504843A5 (enExample) | ||
| WO2017049036A1 (en) | Use of kinase inhibitors to manage tuberculosis and other infectious diseases | |
| US20070265344A1 (en) | Non-steroidal anti-inflammatory oral powder and liquid preparations for administration to animals | |
| WO2014163030A1 (ja) | 馬の炎症治療のための製剤 | |
| MX2023010847A (es) | Formulaciones de tasipimidina y uso de las mismas. | |
| KR20150023831A (ko) | 살외부기생충성 스피노사드로의 고양이 치료를 위한 단일 용량 경구 제제 및 방법 | |
| JP2019514977A5 (enExample) |